LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom. LeadArtis is a partner in the Immunostimulatory Agonist Antibodies for Cancer Therapy effort, a 6.9M€ funding initiative which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). The IACT program aims to translate the agonist IS-Ab concept into immune oncology treatments (http://www.iact-project.eu/). Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept. Analogous SME-driven effort aims at the development of 2nd generation agonist IS-Abs with superior therapeutic index. LeadArtis is applying its Biespecific TrimerbodyTM technology for the generation of novel tumor targeting immune stimulating multivalent antibodies.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...